A new trading day began on Monday, with Lineage Cell Therapeutics Inc (AMEX: LCTX) stock price down -6.90% from the previous day of trading, before settling in for the closing price of $0.59. LCTX’s price has ranged from $0.48 to $1.61 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 148.63% over the last five years. Meanwhile, its annual earnings per share averaged 6.94%. With a float of $218.96 million, this company’s outstanding shares have now reached $220.42 million.
The firm has a total of 75 workers. Let’s measure their productivity. In terms of profitability, gross margin is 90.99%, operating margin of -260.7%, and the pretax margin is -229.91%.
Lineage Cell Therapeutics Inc (LCTX) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Lineage Cell Therapeutics Inc is 0.66%, while institutional ownership is 43.58%. The most recent insider transaction that took place on Nov 26 ’24, was worth 8,850. In this transaction Chief Financial Officer of this company bought 15,000 shares at a rate of $0.59, taking the stock ownership to the 25,500 shares. Before that another transaction happened on Nov 26 ’24, when Company’s General Counsel bought 15,000 for $0.60, making the entire transaction worth $9,000. This insider now owns 22,184 shares in total.
Lineage Cell Therapeutics Inc (LCTX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 6.94% per share during the next fiscal year.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Trading Performance Indicators
Here are Lineage Cell Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.48. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.89.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.11, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.11 in one year’s time.
Technical Analysis of Lineage Cell Therapeutics Inc (LCTX)
Analysing the last 5-days average volume posted by the [Lineage Cell Therapeutics Inc, LCTX], we can find that recorded value of 4.86 million was lower than the volume posted last year of 6.71 million. As of the previous 9 days, the stock’s Stochastic %D was 63.84%. Additionally, its Average True Range was 0.05.
During the past 100 days, Lineage Cell Therapeutics Inc’s (LCTX) raw stochastic average was set at 13.99%, which indicates a significant decrease from 53.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 85.10% in the past 14 days, which was lower than the 92.91% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6751, while its 200-day Moving Average is $0.9282. Now, the first resistance to watch is $0.5913. This is followed by the second major resistance level at $0.6331. The third major resistance level sits at $0.6573. If the price goes on to break the first support level at $0.5253, it is likely to go to the next support level at $0.5011. Should the price break the second support level, the third support level stands at $0.4593.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Key Stats
With a market capitalization of 121.10 million, the company has a total of 220,416K Shares Outstanding. Currently, annual sales are 8,950 K while annual income is -21,490 K. The company’s previous quarter sales were 3,780 K while its latest quarter income was -3,030 K.
